MiNK Therapeutics, Inc. 8-K

What Happened

• On March 31, 2026, MiNK Therapeutics, Inc. (INKT) announced its financial results for the quarter and year ended December 31, 2025 and furnished a press release as Exhibit 99.1 to a current report on Form 8-K (Item 2.02). The Form 8-K was signed by CEO Jennifer S. Buell, Ph.D.

Key Details

• Filing date: March 31, 2026 (Form 8-K).
• Reported period: quarter and year ended December 31, 2025 (Item 2.02).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Cover page interactive XBRL data included (Inline XBRL embedded).

Why It Matters

• The company publicly disclosed its quarterly and full-year 2025 results; those details (revenue, earnings, cash position and other metrics) are contained in the furnished press release and related filings. Investors should review Exhibit 99.1 and the company’s subsequent SEC filings (e.g., 10-K) for the specific financial figures and management commentary, as those numbers can influence the stock price and near-term expectations.